Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer is a research paper published in Future Oncology (2015). On theSindex it has a DataRank of 3.8. It has been cited 93 times, with 89 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.681
From this paper's citation signal
Citation Network Contribution
3.2
From 74 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 89 citers.
MeSH Terms
Keywords
Additional file 1 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer
Additional file 1 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer
Additional file 2 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer
Additional file 2 of BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer